MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced the appointment of Rita Johnson-Greene as chief financial officer.
The company said Johnson-Greene brings more than 20 years of experience in the healthcare sector.
Johnson-Greene most recently served as chief operating officer at the Alliance for Regenerative Medicine, where she oversaw operations, finance and global expansion efforts related to cell and gene therapies.
Previously, she was vice president of sales and Qualified Treatment Centers at Genetix Biotherapeutics, formerly known as bluebird bio, supporting the launch of gene therapy products Zynteglo and Skysona.
She also held senior leadership roles at Spark Therapeutics, where she supported the launch of Luxturna, and earlier worked in finance, commercial operations and sales roles at AstraZeneca in North and South America.
Johnson-Greene began her career in strategic consulting with Accenture’s strategy practice.
In a statement, Ocugen Chairman and CEO Dr. Shankar Musunuri said the appointment comes as the company prepares to submit the first of three planned Biologics License Applications this year. A Biologics License Application is a request for approval from the U.S. Food and Drug Administration to market a biological product in the United States.
Johnson-Greene holds a master of business administration in finance and strategic management from The Wharton School of the University of Pennsylvania and a bachelor’s degree in electrical computer engineering from Drexel University.
Ocugen is developing gene therapies for blindness-related diseases, including retinitis pigmentosa, Stargardt disease and geographic atrophy, a late-stage form of dry age-related macular degeneration.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.